Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pelthos Therapeutics (PTHS) Total Non-Current Liabilities (2024 - 2025)

Pelthos Therapeutics has reported Total Non-Current Liabilities over the past 2 years, most recently at $61.5 million for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $61.5 million for Q4 2025, up 1405.41% from a year ago — trailing twelve months through Dec 2025 was $61.5 million (up 1405.41% YoY), and the annual figure for FY2025 was $61.5 million, up 1405.41%.
  • Total Non-Current Liabilities for Q4 2025 was $61.5 million at Pelthos Therapeutics, up from $42.0 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for PTHS hit a ceiling of $61.5 million in Q4 2025 and a floor of $4.1 million in Q4 2024.